Trop2-Binding Peptide Composition for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective peptides for targeting Trop2 for cancer treatment, particularly in highly resistant cancers like triple-negative breast cancer and cholangiocarcinoma, and there is a need for improved cancer diagnosis, drug delivery, and imaging methods.
Innovation Solution
A peptide with the amino acid sequence CSTLNVESC (SEQ ID NO: 1) specifically binds to Trop2, enabling compositions for cancer diagnosis, drug delivery, and imaging, and a fusion peptide combining this with a cell-permeable and proapoptotic peptide for targeted cancer therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If a small peptide is used for tumor targeting, then deep tissue penetration and low immunogenicity are improved, but circulation time in the bloodstream is reduced
Solution Approach 1:
The patent uses a composite structure by conjugating the targeting peptide (CSTLNVESC) with a carrier protein (albumin or immunoglobulin). This composite construction allows the small peptide to maintain its deep tissue penetration capability while the large carrier protein extends the circulation time in the bloodstream, effectively resolving the contradiction between penetration speed and circulation duration.
2Reliability
If antibodies are used for tumor targeting, then affinity and stability are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent extracts only the essential targeting function from the complex antibody structure by identifying and isolating the specific amino acid sequence (CSTLNVESC) that binds to Trop2. This extracted peptide maintains the targeting affinity while dramatically reducing the molecular complexity compared to full-length antibodies, making the system simpler and more manufacturable.
3Adaptability or versatility
If conventional cancer treatments are used, then general cancer coverage is achieved, but effectiveness against resistant cancers like triple-negative breast cancer and cholangiocarcinoma is insufficient
Solution Approach 1:
The patent applies local quality by designing a highly specific peptide (CSTLNVESC) that targets Trop2 expression locally present on certain cancer cells. Rather than using a general treatment approach, the peptide concentrates its binding activity on cells expressing Trop2, providing effective targeted therapy for resistant cancers while sparing normal cells that do not express the target.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide effectively targets Trop2-expressing cancers, enhancing drug delivery and reducing side effects while providing diagnostic and imaging capabilities, offering therapeutic options for resistant cancers.
Implementation Method 1
A peptide with the amino acid sequence CSTLNVESC (SEQ ID NO: 1) specifically binds to Trop2
Data Source
AI summary
The present disclosure relates to a peptide binding to Trop 2 and a use thereof, wherein, in an attempt to find a peptide having an ability of specifically binding to Trop 2, a peptide (amino acid sequence: CSTLNVESC (SEQ ID NO: 1)) that selectively binds to Trop 2 was discovered using a phage display technique. Targeting cancers that are highly resistant to anticancer drugs in breast cancer (in particular, triple-negative breast cancer), pancreatic cancer, and cholangiocarcinoma while having no effective treatments, an effective anticancer drug may be prepared by delivering cancer-specific drugs or developing targeted therapeutic agents using the peptide of the present disclosure.